Categories: Press Release

APAC Cell and Gene Therapy Biomanufacturing Market to Reach $8.60 Billion by 2031: BIS Research

Progress in cell and gene-based therapies is prompting efforts to commercialize effective treatments. The growing need for cell manufacturing and comprehensive clinical data underscores the importance of prioritizing efficient and scalable biomanufacturing. The increased demand for these therapies drives biomanufacturers specializing in cell and gene therapy expansion and market consolidation.

The Asia-Pacific (APAC) region is experiencing rapid growth in the cell and gene therapy biomanufacturing market, fueled by a robust clinical pipeline, a rising number of developers, and an increasing focus on target indication groups.

According to the BIS Research market intelligence report, the APAC cell and gene therapy biomanufacturing market was valued at $1.81 billion in 2021 and is expected to reach $8.60 billion by the end of 2031, growing at a CAGR of 17.88% during the forecast period 2022-2031.

Market Analysis: Trends, Data, and Growth Projections

A prominent theme is the ongoing expansion of therapeutic applications, demonstrating the potential to address a growing array of medical conditions. Notably, advancements in chimeric antigen receptor T-cell (CAR-T) treatments are revolutionizing cancer treatment by explicitly targeting antigens on cancer cells.

The development of clustered regularly interspaced short palindromic repeats (CRISPR)-based gene-editing medicines open new avenues for addressing rare diseases and genetic abnormalities. Regulatory adjustments in response to these breakthroughs have led to increased approvals of gene and cell therapies in multiple countries, expanding access to a broader patient population.

Collaboration and investment from pharmaceutical companies, academic institutions, and startups are driving further innovation in this rapidly evolving field.

BIS Research, a leading market research firm, has released a report titled, APAC Cell and Gene Therapy Biomanufacturing Market, which discusses the challenges, growth factors, and future opportunities driving the remarkable growth of the APAC cell and gene therapy biomanufacturing market.

Key Players and Market Segments

WuXi AppTec is a significant player in the global APAC cell and gene therapy biomanufacturing market.

The BIS Research report on the APAC cell and gene therapy biomanufacturing market is categorized by product, end user, and country. Consumables are projected to be the dominant product segment in the market. Contract manufacturing organizations (CMOs) are anticipated to exhibit the highest growth among the end user segment during the forecast period 2022-2031, with an expected CAGR of 21.07%.

Given the concentration of most established companies in this region, China takes the lead in the Asia-Pacific cell and gene therapy biomanufacturing market. The market in the region is forecasted to reach $2.71 billion by 2031, growing at a CAGR of 20.04%.

Market Drivers, Opportunities, and Challenges

Growth in the APAC cell and gene therapy biomanufacturing market is fueled by regulatory advancements, ongoing research initiatives, and collaborations among industry leaders.

As per the market intelligence report from BIS Research, the APAC cell and gene therapy biomanufacturing market achieved a valuation of $1.81 billion in 2021 and is projected to reach $8.60 billion by the end of 2031, with a CAGR of 17.88% during the forecast period spanning from 2022 to 2031.

The expansion of target indications for cell and gene therapies is a significant driver for the APAC cell and gene therapy biomanufacturing market, resulting in an escalating demand for large-scale biomanufacturing. The entry of new participants into the cell and gene therapy market amplifies the need for biomanufacturing facilities and equipment, a trend expected to persist over the next decade. A robust clinical pipeline also contributes to the sustained demand for biomanufacturing infrastructure.

Despite the strong growth potential, the high initial costs associated with establishing biomanufacturing facilities pose a considerable constraint on the market.

Report Focus and Methodology

The APAC cell and gene therapy biomanufacturing market report provides a credible global and regional market analysis. The report profiles existing and upcoming products, types, applications, end users, and key players in the market.

BIS Research follows an effective market intelligence methodology comprising a crucial 15-step process. Data is captured from reliable, intelligent sources such as expert interviews, patents, web analytics, scholarly articles, scientific publications, and research and development literature.

BIS follows the Deep Tech M-A-P™ approach, which includes market, application, and product within the syndicate and custom research projects.

M– The Market section covers industry overview, business dynamics, competitive benchmarks, and company profiles. It provides insights to enter, expand, or exit markets globally, regionally, or locally.

A– The Application section delves into product analyses, technology insights, use cases, and user types. Precise market estimates and forecasts back this data.

P- The Product section covers products, parts, technologies, and materials. Companies looking to drive an innovative agenda need information about product definitions, demand analysis, technology benchmarking and roadmaps, patents, and pricing analysis.

Analyst Note

According to BIS Research principal analyst, healthcare, “The APAC cell and gene therapy biomanufacturing market is being propelled by the increasing prevalence of diseases such as orphan diseases, cancers, metabolic disorders, and autoimmune disorders, along with the growing approval of cell and gene therapies in the region. The market has seen a rise in new entrants and investments in these therapies, boosting the demand for consumables, equipment, and software used in manufacturing. This trend is anticipated to continue in the foreseeable future, leading to a substantial impact on the global cell and gene therapy biomanufacturing market.”

About BIS Research

BIS Research is a global B2B market intelligence and advisory firm focusing on deep technology and related emerging trends, which can disrupt the market dynamics in the near future. We publish over 200 market intelligence studies annually, focusing on several deep technology verticals.

Our strategic market analysis emphasizes market estimations, technology analysis, emerging high-growth applications, deeply segmented granular country-level market data, and other important market parameters useful in the strategic decision-making for senior management.

BIS Research offers syndicate as well as custom studies and expert consultations to firms, providing them with specific and actionable insights on novel technology markets, business models, and competitive landscapes.